Department of Internal Medicine, Institute for Complementary Medicine, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland.
J Ethnopharmacol. 2011 Mar 24;134(2):228-33. doi: 10.1016/j.jep.2010.12.006. Epub 2010 Dec 16.
A special ethanolic-aqueous extract from seven traditional medicinal plants (BNO 1030) has been used for several decades to treat recurrent infections of the respiratory tract. Considering the potential role of interleukin-8 (IL-8) and human beta defensin-2 (hBD-2) in inflammation, we investigated the effect of BNO 1030 on lipopolysaccharide (LPS) from Pseudomonas aeruginosa or IL-1β-induced inflammatory mediators in A549 human type II alveolar epithelial cells.
A549 cells were stimulated with LPS (100 μg/ml) or IL-1β (50 ng/ml) in the presence of the preparation and the secretion of IL-8 and hBD-2 were measured after 18 h and 24h in cell free supernatants using enzyme-linked immunosorbent assays (ELISA). Cell viability and cell growth was investigated by propidium iodide uptake and WST-1 assay, respectively.
BNO 1030 inhibited the secretion of IL-8 and hBD-2 at non-cytotoxic concentrations (0.1-100 μg/ml; cell growth inhibitory concentration, 50% (IC(50))=678 ± 87.6 μg/ml). Stimulation by IL-1β led to a 7-fold activation of IL-8 secretion, which was reduced by 37.7 ± 4.1% (p<0.05) after incubation with 100 μg/ml BNO 1030. Inducible hBD-2 was suppressed by 91.8 ± 15.6% (p<0.01) at the same concentration of BNO 1030 (IC(50)=0.7 ± 0.1 μg/ml). The 2-fold increase of IL-8 secretion by LPS-stimulated cells was completely abolished at concentration of 50 μg/ml BNO 1030 (IC(50)=5.7±3.6 μg/ml).
BNO 1030 suppressed the secretion of IL-8 and hBD-2 in cultured epithelial A549 cells. These results support its use as a phytotherapeutic product prepared from traditional remedies in inflammatory diseases, especially those affecting the respiratory tract.
一种特殊的含醇-水溶液提取物（BNO 1030）已被用于治疗呼吸道的复发性感染，使用了几十年。鉴于白细胞介素-8（IL-8）和人β防御素-2（hBD-2）在炎症中的潜在作用，我们研究了 BNO 1030 对铜绿假单胞菌脂多糖（LPS）或 IL-1β诱导的 A549 人Ⅱ型肺泡上皮细胞炎症介质的影响。
用 LPS（100μg/ml）或 IL-1β（50ng/ml）刺激 A549 细胞，用酶联免疫吸附试验（ELISA）在细胞上清液中分别测量 18 小时和 24 小时后 IL-8 和 hBD-2 的分泌。通过碘化丙啶摄取和 WST-1 测定分别研究细胞活力和细胞生长。
BNO 1030 在非细胞毒性浓度（0.1-100μg/ml；细胞生长抑制浓度，50%（IC50）=678±87.6μg/ml）下抑制 IL-8 和 hBD-2 的分泌。IL-1β刺激导致 IL-8 分泌增加 7 倍，用 100μg/ml BNO 1030 孵育后减少 37.7±4.1%（p<0.05）。相同浓度的 BNO 1030 抑制诱导型 hBD-2 表达 91.8±15.6%（p<0.01）（IC50=0.7±0.1μg/ml）。50μg/ml BNO 1030 可完全抑制 LPS 刺激细胞 IL-8 分泌增加 2 倍（IC50=5.7±3.6μg/ml）。
BNO 1030 抑制培养上皮 A549 细胞中 IL-8 和 hBD-2 的分泌。这些结果支持其作为一种从传统药物制备的植物疗法产品在炎症性疾病中的应用，特别是在影响呼吸道的疾病中。
